Cardiac injury has been reported in patients with COVID-19, and is related to an increased risk of mortality. However, it is not clear whether cardiac dysfunction is caused by direct SARS-CoV-2 infection of cardiac tissue or induced by inflammation. To investigate the mechanisms underlying cardiac dysfunction in patients with COVID-19, James Hudson and colleagues applied human pluripotent stem cell-derived cardiac organoids in combination with phosphoproteomics and single nuclei RNA sequencing. The multicellular organoid model, which contains a complex mixture of self-organizing cells, including epicardial, cells, fibroblasts, pericytes, endothelial cells and cardiomyocytes, allows rapid screening of cytokine combinations and drug candidates. Using this model, the researchers showed that an inflammatory, COVID-19-induced cytokine storm causes diastolic dysfunction. A targeted drug screen then revealed bromodomain and extraterminal family (BET) inhibitors as candidates to prevent COVID-19-mediated cardiac damage.
References
Original article
Mills, R. J. et al. BET inhibition blocks inflammation-induced cardiacdysfunction and SARS-CoV-2 infection. Cell 184, 1–16 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Horejs, C. The cause of cardiac dysfunction. Nat Rev Mater 6, 380 (2021). https://doi.org/10.1038/s41578-021-00318-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41578-021-00318-8